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Ursodeoxycholic acid (UDCA) is a standard treatment in
several cholestatic liver diseases (Figure 1A) [1]. In vivo,
conjugation with taurine occurs rapidly and yields taur-
oursodeoxycholic acid (TUDC), which has been shown
to promote choleresis by triggering the insertion of
ATP-dependent transport proteins (e.g., the bile salt
export pump (Bsep) and the multidrug resistance pro-
tein-2 (Mrp2)) into the canalicular membrane [2].
TUDC-induced recruitment of Bsep results from activa-
tion of focal adhesion kinase (FAK), phosphatidylinositol
3-kinase (PI3 kinase), and c-Src, which leads to down-
stream activation of extracellular signal-regulated
kinases (Erks) and p38 mitogen-activated protein kinase
(p38MAPK). Upon hepatocyte swelling, either induced by
exposure to a hypoosmotic environment or insulin, a5b1
integrins become activated and trigger similar signaling
events towards choleresis. a5b1 Integrins may also
become activated by a swelling-independent way as pre-
viously shown by exposing hepatocytes to pathophysio-
logical concentrations of urea [3]. Both TUDC-induced
and swelling-dependent signaling were abolished in the
presence of an antagonistic, RGD-motif containing
hexapeptide (GRGDSP).
These findings led us to hypothesize that a5b1 integrin
will act as a receptor for TUDC in hepatocytes. We tested
this hypothesis in a combined experimental and computa-
tional study [4]. Immunofluorescence staining on cryosec-
tions of isolated perfused rat liver (IPRL) revealed the
active conformation of b1 integrin within 1 min after addi-
tion of TUDC at a concentration of 20 µM. Furthermore,
phosphorylation of Erk-1 and -2 as well as activation of
the epidermal growth factor receptor were induced by
TUDC within the same time span. These effects were sensi-
tive to inhibition by GRGDSP but insensitive to the pre-
sence of an inactive control peptide (GRADSP). As TUDC
does not affect hepatocyte volume, which excludes that
TUDC triggers integrin activation osmotically, these find-
ings demonstrated that TUDC directly activates a5b1 integ-
rins and triggers signaling events towards choleresis. While
swelling-induced b1 integrin activation occurs primarily in
the plasma membrane, TUDC-induced b1 integrin activa-
tion occurs primarily in the cytosol of hepatocytes. We
demonstrated that the presence of the Na+/taurocholate
cotransporting polypeptide (Ntcp) is required for the latter.
The need to uptake and/or concentrate TUDC inside the
hepatocyte for b1 integrin activation to occur may explain
why TUDC primarily acts in the liver.
In order to provide insights at a molecular level as to
how TUDC activates a5b1-integrin, a complex structure of
a homology model of the ectodomain of a5b1-integrin and
TUDC was generated by molecular docking and subse-
quently subjected to molecular dynamics (MD) simula-
tions of 200 ns length [4]. These simulations revealed
pronounced conformational changes in three regions of
the bA domain of the integrin (Figure 1B): I) Helix a1
straightens and becomes continuous; II) this leads to a
tighter packing between the top of helix a7 and the center
of a1, which has been characterized as “T-junction forma-
tion” in an X-ray structure of integrin aIIbb3 bound to a
ligand as well as in computational studies of agonist-
bound integrins; III) as a result, helix a7 moves down-
wards and outwards, which imposes a torque on the
hybrid domain. The induced rotational motion of the
hybrid domain is a prerequisite for the unbending of the
integrin ectodomain, which, in turn, is required for integ-
rin activation according to current models. Neither did
MD simulations of the ectodomain of a5b1 integrin bound
to GRGDSP nor to taurocholic acid (TC) (Figure 1A)
reveal such conformational changes, in line with results
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from immunofluorescence staining of IPRL that did not
reveal an appearance of the active conformation of
b1-integrin upon addition of TC either. The bile acids gly-
cochenodeoxycholic acid (GCDC), taurochenodeoxycholic
acid (TCDC), or taurolithocholic acid 3-sulfate (TLCS)
were likewise ineffective with respect to b1 integrin activa-
tion according to immunofluorescence staining. All these
bile acids differ from TUDC with respect to the configura-
tion and/or presence or absence of functional groups in
the cholane moiety.
In contrast, the taurine conjugate (TnorUDCA) of nor-
UDCA (Figure 1A), a C23 homolog of UDCA that lacks
a methylene group in the sidechain, is moderately effec-
tive in exerting anticholestatic effects in experimental
hepatocellular cholestatis [5]. Preliminary results from
immunofluorescence staining of IPRL indicate that
TnorUDCA and norUDCA can activate b1 integrins,
with stronger effects observed with norUDCA. Another
sidechain modification occurs if glycine rather than
taurine is conjugated with the bile acid in the terminal
synthesis step. Preliminary results from immunofluores-
cence staining indicate that the glyco-conjugated UDCA
(GUDC; Figure 1A) does not activate b1 integrins
although GUDC can be transported by the Ntcp [6]. In
order to investigate the bile acids’ modes of action at a
molecular level, we subjected norUDCA and GUDC
bound to the ectodomain of a5b1 integrin to MD simu-
lations, employing the same setup as for the simulations
above. In addition, we also performed MD simulations
of the complex of a5b1 integrin with the unconjugated
UDCA as well as of a ligand-free structure of the a5b1
ectodomain for reference. Together with the above
results for TUDC and TC-bound a5b1 integrin, these
simulations reveal a significant correlation between
characteristic conformational changes in the bA domain
and the potential of the bile acid to activate b1 integrins
as observed in immunofluorescence staining: I) the
higher this potential (TUDC, norUDCA), the less is
helix a1 kinked and the more is helix a7 tilted with
respect to the ligand-free structure; II) changes in the
opposite direction are observed for the non-activating
bile acids (TC, GUDC); III) the MD simulations reveal
that changes of helix a1 towards an activated integrin
state are more pronounced than those of helix a7.
According to these preliminary results, we predict that
UDCA does not activate b1 integrins because the con-
formational characteristics of helices a1 and a7 observed
with this bile acid do not differ much from those of the
ligand-free structure. Finally, the MD simulations sug-
gest that the cholane scaffolds of TUDC and norUDCA
adopt different binding modes in the cleft between the
propeller and bA domains of a5b1 integrin; yet, the
Figure 1 (A) Scaffold and R-groups of the investigated bile acid derivatives. (B) Overlay of the starting structure of MD simulations of a5b1-
integrin bound to TUDC (transparent) and the structure closest to the average as determined over the trajectory of 200 ns length (solid). For
clarity, only the bA domain of a5b1-integrin is shown together with three Mg
2+ ions (red spheres); TUDC was omitted. Three regions of
characteristic conformational changes in the bA domain are visible: I) straightening of helix a1 (orange); II) T-junction formation between helices
a1 and a7; III) tilting of helix a7 (blue).
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activating effects of both bile acids is funneled through
helix a1 and from there leads to allosteric changes in the
bA domain that propagate towards the hybrid domain.
In summary, in a combined computational and experi-
mental study, we showed that TUDC directly activates a5b1
integrins inside hepatocytes and induces conformational
changes in the b1 subunit that lead to integrin activation
and swelling-independent signaling towards choleresis. A
bile acid with a norursodeoxycholane scaffold (norUDCA)
was shown to activate b1 integrins even without conjuga-
tion. In contrast, bile acids modified in the cholane scaffold
(TC, TCDC, TLCS) or conjugated to glycine (GCDC,
GUDC) were shown to be non-activating. This suggests a
unique role of the (nor)ursodeoxycholane scaffold for direct
interaction with and activation of a5b1 integrins in connec-
tion with no or a taurine conjugation.
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